A5002569209- Natural product bioactivities and synthesis
- Melanoma and MAPK Pathways
- Computational Drug Discovery Methods
- Phytochemistry and Biological Activities
- Natural Antidiabetic Agents Studies
- Animal testing and alternatives
- Plant biochemistry and biosynthesis
- Ginseng Biological Effects and Applications
- Phytochemicals and Antioxidant Activities
- Colorectal Cancer Treatments and Studies
- Fungal Biology and Applications
- Bladder and Urothelial Cancer Treatments
- Cancer Mechanisms and Therapy
- Microbial Metabolic Engineering and Bioproduction
- melanin and skin pigmentation
- Algal biology and biofuel production
- Biological Activity of Diterpenoids and Biflavonoids
- Hepatocellular Carcinoma Treatment and Prognosis
- Cholesterol and Lipid Metabolism
- Essential Oils and Antimicrobial Activity
- Biofuel production and bioconversion
- Urinary and Genital Oncology Studies
- Health Systems, Economic Evaluations, Quality of Life
- Carcinogens and Genotoxicity Assessment
- Steroid Chemistry and Biochemistry
Hanmi Pharmaceutical (South Korea)
2019-2024
Sungkyunkwan University
2024
MSD (South Korea)
2024
Ministry of Food and Drug Safety
2018-2019
National Institute of Food and Drug Safety Evaluation
2018-2019
Dongduk Women's University
2016
Helixmith (South Korea)
2008
Kyung Hee University
2005-2007
Liquid C1 feedstock, including methanol, formaldehyde and formic acid can be easily manufactured from greenhouse gases CO2 CH4. Yarrowia lipolytica, isolated marine ecosystem, is a non-conventional yeast which capable of assimilating multiple range hydrophobic compounds alcohols, lipids, hydrocarbons, volatile fatty acids et al. This has been extensively engineered to produce carotenoids, squalene other natural products. Herein we tested the growth fitness Y. lipolytica when exposed various...
3000 Background: Belvarafenib (HM95573/GDC-5573) is an oral type II pan-RAF kinase inhibitor which demonstrates selective anti-tumor activity in several non-clinical cancer models and patients with RAS- or RAF- mutation. Here we present overall safety efficacy findings of two phase 1 studies, consisting dose escalation expansion stages. Methods: Patients advanced solid cancers harboring documented mutation were enrolled. In the study, treated at a starting 50 mg once daily (QD) to 800 BID...
3007 Background: Belvarafenib, a potent, selective RAF dimer (type II) inhibitor, exhibits clinical activity in BRAF V600E - and NRAS-mutant (NRASm) melanoma patients. The combination of belvarafenib cobimetinib more potently durably suppressed MAPK pathway output tumor growth than currently approved BRAF/MEK inhibitors RAS- or RAF-mutant xenograft models. This interim results phase 1b trial evaluated the safety, tolerability, pharmacokinetics, anti-tumor with dose-escalation NRASm patients...
Background The JAVELIN Bladder 100 phase 3 trial demonstrated the efficacy and safety of avelumab administered as first-line (1L) maintenance treatment in patients with advanced urothelial carcinoma (UC) without disease progression after 1L platinum-based chemotherapy. This study provides first real-world data from Korea regarding treatment, comprising obtained a nationwide expanded access program (EAP). Methods open-label EAP was conducted at five centers September 2021 until June 2023....
We showed recently that ginsenosides inhibit the activity of various types ion channel. Here we have investigated role carbohydrate component ginsenoside Rg3 in inhibition Na+ channels. The channels were expressed Xenopus oocytes by injecting cRNAs encoding rat brain Nav1.2 α and β1 subunits, analyzed two-electrode voltage clamp technique. Treatment with reversibly inhibited inward peak current (INa) an IC50 32.2 ± 4.5 μM, was voltage-dependent. To examine sugar moiety, prepared a straight...
Abstract Acquisition of ARAF mutations upon treatment with the potent and selective RAF dimer (type II) inhibitor belvarafenib has been previously observed, but whether these alterations or others are observed in patients treated a combination MEK cobimetinib is unknown. The mutational profiles from circulating tumor DNA (ctDNA) were determined using FoundationOne liquid ctDNA assay paired baseline (BL) end (EOT) peripheral blood samples 79 locally advanced metastatic RAS-mutant solid tumors...
Abstract Background Melanoma incidence is on the rise in East Asia, yet studies of molecular landscape are lacking this population. We examined patients with melanoma who underwent next-generation sequencing (NGS) at a single tertiary center South Korea, focusing harboring NRAS or RAF alterations received belvarafenib, pan-RAF dimer inhibitor, through Expanded Access Program (EAP). Patients and Methods Data were collected from 192 NGS between November 2017 May 2023. Variant call format data...
목ì 본 ì°êµ¬ë ë ¸ë£¨ê¶ë ì´ ë²ì¯ ì¶ì¶ë¬¼ì ë©ë¼ë í©ì± ë° ì°í ì¤í¸ë ì¤ ì¡°ì ì 미ì¹ë ìí¥ì ì¡°ì¬íëë° ê·¸ ì´ ìë¤. ë°©ë² ë²ì¯ì ê°ê° 95% ìíì¬ê³¼ ì¦ë¥ìë¡ ì¶ì¶íìê³ , ìíì¬ ì¶ì¶ë¬¼ì ë¤ì ì¦ë¥ìì í´ë¡ë¡í¬ë¦ì¼ë¡ ë¶ííìë¤. í©ì±ëì B16F1 ì¸í¬ë¥¼ íµí´ íì¸íìê³ ì¸í¬ ë ì±ì ì¸í¬ì HaCaT MTT assay ë°©ë²ì¼ë¡ íì¸íìë¤. ëí, β-catenin/Tcf íì±ì luciferase assay를 측ì...
We made gene therapeutics for X-chronic granulomatous disease (CGD) by transducing murine bone marrow-derived stem cells with MT-gp91 retrovirus and evaluated possible toxicity in mice as a prerequisite human clinical trials. Male C57BL/6 were injected intravenously X-CGD twice at an interval of two weeks 5 x 10(7) cells/kg sacrificed 2 after the last administration. Significant changes noted X-CGD-treated animals increase white blood cell counts slight decrease albumin/globulin ratio. The...